Vanguard Group Inc Pharma Cyte Biotech, Inc. Transaction History

Vanguard Group Inc

$5.57 Trillion
Q4 2024

A detailed history of Vanguard Group Inc transactions in Pharma Cyte Biotech, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 192,387 shares of PMCB stock, worth $319,362. This represents 0.0% of its overall portfolio holdings.

Number of Shares

192,387

Previous 192,387 -0.0%

Holding current value

$319,362

Previous $367,000 18.26%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.95 - $2.52 $34,680 - $44,818	17,785 Added 10.19%	192,387 $377,000
Q1 2024 May 10, 2024	BUY	$1.95 - $2.48 $6,370 - $8,102	3,267 Added 1.91%	174,602 $413,000
Q4 2023 Feb 14, 2024	BUY	$2.01 - $2.34 $4,852 - $5,648	2,414 Added 1.43%	171,335 $370,000
Q3 2023 Nov 14, 2023	SELL	$2.09 - $2.89 $30,641 - $42,370	-14,661 Reduced 7.99%	168,921 $354,000
Q2 2023 Aug 14, 2023	SELL	$2.74 - $3.18 $1.42 Million - $1.65 Million	-517,868 Reduced 73.83%	183,582 $525,000
Q1 2023 May 15, 2023	BUY	$2.83 - $3.03 $132,820 - $142,206	46,933 Added 7.17%	701,450 $2.04 Million
Q4 2022 Feb 10, 2023	BUY	$2.39 - $3.07 $27,109 - $34,823	11,343 Added 1.76%	654,517 $1.92 Million
Q3 2022 Nov 14, 2022	BUY	$2.24 - $2.85 $1,792 - $2,280	800 Added 0.12%	643,174 $1.54 Million
Q2 2022 Aug 12, 2022	BUY	$1.99 - $2.33 $55,220 - $64,655	27,749 Added 4.51%	642,374 $1.44 Million
Q1 2022 May 13, 2022	BUY	$1.91 - $2.77 $1,831 - $2,656	959 Added 0.16%	614,625 $1.41 Million
Q4 2021 Feb 14, 2022	BUY	$2.4 - $3.19 $1.47 Million - $1.96 Million	613,666 New	613,666 $1.53 Million

Others Institutions Holding PMCB

# of Institutions

Shares Held

706K

Call Options Held

9.3K

Put Options Held

4.6K

View Full List

About PharmaCyte Biotech, Inc.

Ticker PMCB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,750,100
Market Cap $34.4M
Description
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types o...

More about PMCB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Pharma Cyte Biotech, Inc. Transaction History